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Abstract
Background: In the emergency department (ED), extracorporeal membrane oxygenation (ECMO) can be used
as a rescue treatment modality for patients with refractory circulatory and/or respiratory failure. Serious
consideration must be given to the indication, and the PRESERVE and RESP scores for mortality have been
investigated. However these scores were validated to predict survival in patients who received mainly veno-venous
(VV) ECMO in the intensive care unit. The aim of the present study was to investigate the factors that predicted the
outcomes for patients who received mixed mode (veno-arterial [VA] and VV) ECMO support in the ED.
Methods: This single center retrospective study included 65 patients who received ECMO support at the ED for
circulatory or respiratory failure between January 2009 and December 2013. Pre-ECMO SAPS II and other variables
were evaluated and compared for predicting mortality.
Results: Fifty-four percent of patients received ECMO-cardiopulmonary resuscitation (E-CPR), 31 % received VA and
V-AV ECMO, and 15 % received VV ECMO. The 28-day and 60-month mortality rates were 52 % and 63 %. In the
multivariate analysis, only the pre-ECMO Simplified Acute Physiology Score II (SAPS II) (odd ratio: 1.189, 95 %
confidence interval: 1.032–1.370, p = 0.016) could predict the 28-day mortality. The area under the receiver
operating characteristic curve and the optimal cutoff value for pre-ECMO SAPS II in predicting 28-day mortality was
0.852 (95 % CI: 0.753–0.951, p < 0.001) and 80 (sensitivity of 97.1 % and specificity of 71.0 %), respectively. Validation
of the 80 cutoff value revealed a statistically significant difference for the 28-day and 60-month mortality rates in
the overall, E-CPR, and VA groups (28-day: p < 0.001, p = 0.004, p = 0.005; 60-month: p < 0.001, p = 0.004, p = 0.020).
In the Kaplan-Meier analysis, the 28-day and 60-month survival rates were lower among the patients with a
pre-ECMO SAPS II of ≤80, compared to those with a score of >80 (both, p < 0.001).
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Conclusion: The pre-ECMO SAPS II could be helpful for identifying patients with refractory acute circulatory and/or
respiratory failure who will respond to ECMO support in the ED.
Keywords: SAPS II, Extracorporeal membrane oxygenation, Emergency department, Circulatory failure, Respiratory
failure
Background
Patients with acute circulatory and/or acute respiratory
failure in the emergency department (ED) must be diag-
nosed rapidly and accurately, and an optimal treatment
plan must be established according to their initial diag-
nosis. Unfortunately, many patients’ condition rapidly
deteriorates before an accurate diagnosis, despite the use
of a vasopressor and mechanical ventilator. In this con-
text, extracorporeal membrane oxygenation (ECMO)
can be used as a rescue treatment to stabilize their con-
dition and provide additional time to reach an accurate
diagnosis, which ultimately leads to improvements in
survival rates.
ECMO has recently become increasingly popular for
treating patients with acute heart and/or respiratory fail-
ure or arrest who do not respond to conventional treat-
ment [1–9]. However, serious consideration must be
given to the therapeutic indication for ECMO, due
to the high economic cost and labor intensive na-
ture. Therefore, several mortality risk score systems
(PRESERVE and RESP) have been investigated for
identifying patients who are indicated for ECMO
support [10, 11]. However these scores were vali-
dated to predict survival in patients who received
mainly veno-venous (VV) ECMO in the intensive
care unit (ICU). The aim of the present study was to
investigate the factors that predict the outcomes for
patients who received mixed mode (veno-arterial
[VA] and VV) ECMO support in the ED for circula-
tory or respiratory failure.
Methods
Patient enrollment criteria
This study was approved by the institutional review board
of Hallym University Chuncheon Sacred Heart Hospital,
and the requirement for informed consent was waived, due
to the retrospective design. Our search identified 65 pa-
tients with acute circulatory and/or respiratory failure who
did not respond to conventional treatment and received
ECMO at the ED between January 2009 and December
2013 (Fig. 1). The indications for VA ECMO were (1) re-
fractory cardiogenic, septic, or neurogenic shock, with a
systolic blood pressure of <80 mmHg, despite appropriate
conventional treatment; (2) cardiac arrest that did not
present with return of spontaneous circulation within
10 min of cardiopulmonary resuscitation (CPR); and (3) re-
current cardiac arrest within 20 min of return of spontan-
eous circulation after CPR. The indications for VV ECMO
were (1) a ratio of <100 for partial arterial oxygen pressure
to fractional inspired oxygen concentration (PaO2/FiO2)
on FiO2 1.0 or (2) a pH of <7.20 that was caused by the
lack of correction in CO2 retention, despite appropriate
conventional treatment for acute respiratory failure.
In addition, patients who were predicted to require a high
dose of inotropic agents (norepinephrine >0.25 μg/kg/min)
during VV ECMO (due to acute respiratory failure) re-
ceived V-AV ECMO. Furthermore, if a patient presented
with upper limb hypoxia, due to a lack of lung or heart
function recovery in the VA mode, they received V-AV or
VV ECMO. Patients did not receive ECMO in cases of un-
witnessed cardiac arrest, terminal malignancy, or if they
Fig. 1 Flow chart of the study population and outcomes at 28 days. ED: emergency department; ECMO: extracorporeal membrane oxygenation,
E-CPR: ECMO-cardiopulmonary resuscitation, VV: veno-venous, V-AV: veno-arteriovenous
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were unlikely to regain normal function after general
recovery.
Patient data collection
Electronic medical records were reviewed. Pre-ECMO
characteristics (age, sex, body mass index, medical his-
tory, diagnosis, arrest [location, CPR time and complica-
tion, ECMO-cardiopulmonary resuscitation], laboratory
finding, SOFA, pre-ECMO SAPS II, and door-to-ECMO
time) and duration and post-ECMO characteristics
(ECMO modes, anticoagulation, duration, continuous
renal replacement therapy, transfusion, length of stay)
were retrospectively calculated.
ECMO equipment
Three types of centrifugal pumps were used for ECMO.
Until May 2010, the Capiox Emergency Bypass System®
(Terumo, Inc., Tokyo, Japan) and Bio-pump® (Medtronic
Inc., Minneapolis, USA) were used at our institution.
However, since June 2010, the Centrifugal Rotaflow Pump®
(Maquet Inc., Hirrlingen, Germany) has been used for
most patients. The cannulae were 17–21-Fr arterial
cannulae (DLP®, Biomedicus®; Medtronic Inc., or
RMI®; Edward’s Lifesciences LLC, Irvine, CA, USA)
and 17–28-Fr venous cannulae (DLP®, Biomedicus®,
Medtronic Inc., or RMI®, Edward’s Lifesciences LLC),
depending on the patient’s size.
ECMO management
After the injection of a 50–80 IU/kg heparin bolus, all
ECMO patients underwent cannulation using the Seldinger
technique in the cardiac catheterization laboratory, which
is located next to the ED. When nafamostat mesilate (SK
Chemicals Life Science Biz., Seoul, Korea licensed by Torii
Pharmaceutical Co., LTD, Tokyo, Japan) was used for
anticoagulation during the ECMO, the maintenance dose
was held at 0.4–1.5 mg/kg/h to maintain a partial
thromboplastin time of 60–80 s [12]. Patients with pul-
monary embolism or who had not been placed on conti-
nuous renal replacement therapy received heparin. The
ECMO flow was held at 3.0–4.0 L/min to maintain a mean
blood pressure of >60 mmHg, and we administered nor-
epinephrine or dopamine, as necessary, to maintain the ap-
propriate arterial blood pressure. Among the patients who
received E-CPR, those who exhibited a Glasgow Coma
Scale score of <9 (eye response: eyes opening to speech,
motor: obeys commands, verbal: intubated state) after ar-
riving at the intensive care unit (ICU) were subjected to
hypothermic therapy, without the use of sedative drugs, by
maintaining their body temperature at 33–34 °C for 24 h
[13]. Patients who recovered to a Glasgow Coma Scale of
≥9 were immediately placed on sedatives to increase their
body temperature in increments of 0.2 °C/h. During
ECMO, the ventilator mode was maintained at a tidal
volume of 5 mL/kg, the respiratory rate was maintained at
10/min, and the positive end expiratory pressure was main-
tained at 4–8 cm H2O. The FiO2 was held at 0.21–1.0 to
maintain 88–100 % arterial oxygen saturation. During VV-
ECMO, patients with a clear mental state and a predicted
capacity for sputum expectoration were extubated, and
oxygen was supplied through a nasal cannula at 3 L/min
with awakening ECMO. Patients with acute myocardial in-
farction (AMI) received percutaneous coronary interven-
tion (PCI) before or after the ECMO. On the day of the
PCI, the patients received clopidogrel (300 mg) and aspirin
(250 mg), and also received clopidogrel (75 mg) and aspirin
(100–200 mg) on the following day. Hematocrit levels and
platelet counts of 30–35 % and 50,000–80,000/mL, re-
spectively, were targeted, and a blood transfusion was
performed if the level(s) fell below the designated
threshold. In cases of heart function recovery without
lung function recovery during VA-ECMO, which led to
upper body hypoxia (PaO2 of <50 mmHg), the ECMO
mode was changed to V-AV ECMO if the left ventricle
ejection fraction (LVEF) was <30 % (as assessed via
two-dimensional echocardiography), or to VV ECMO if
the LVEF was >30 %.
The use of VA ECMO was discontinued when echocar-
diography revealed an LVEF of >30 % at an ECMO flow of
1 L/min. The use of VV ECMO was discontinued if the
arterial blood gas analysis indicated a pH of >7.25, a PaO2
of 80–120 mmHg, and a PaCO2 of 35–45 mmHg at a flow
of 1–2 L/min. To patients who were receiving VV ECMO,
we delivered a FiO2 of 0.21 (supplied via the gas blender)
and 0 L/min sweep gas, using ventilator settings of: VT of
6 mL/kg, a respiratory rate of 12/min, and 8 cm of H2O
positive end expiratory pressure. Alternatively, a FiO2 of
0.6 or oxygen (3 L/min) was delivered via a nasal cannula
to patients who were awake. Successful ECMO weaning
was defined as patient survival of >24 h after ECMO re-
moval, and the primary end-point was defined as patient
survival of >28 days.
Calculation of pre-ECMO SAPS II
SAPS II is a severity score and mortality estimation tool
that was developed for patients in medical or surgical
ICUs [14, 15]. In this tool, data regarding the worst
physiological variables are collected within the first 24 h
of ICU admission. In this present study, we modified the
SAPS II tool to collect the relevant pre-ECMO data for
patients in the ED by collecting data regarding the worst
variables within the first 24 h after admission to the ED.
In cases of arrest, the heart rate and Glasgow Coma Scale
variables were scored at the lowest value (heart rate of <40
beats/min and Glasgow Coma Scale score of <6). If the
patient died within 24 h, the urine output variable was es-
timated by multiplying the hourly urine output (total
urine output divided by the total time) by 24.
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Statistical analysis
Statistical analyses were performed using IBM SPSS soft-
ware (version 21; IBM Corp., Armonk, NY, USA), and
differences with a p-value of <0.05 were considered sta-
tistically significant. The Mann–Whitney U test was
used to evaluate continuous variables, and Pearson’s chi
square test or Fisher’s exact test was used for categorical
variables. To identify the independent factors that were
associated with patient death, we used univariate and
multivariate stepwise logistic regression analysis models.
The pre-ECMO SAPS II, which was the only significant
factor in the multivariate stepwise logistic regression
analyses, was subjected to receiver operating characteris-
tic curve (ROC) analysis to identify the optimum cutoff
value. Using this cutoff score, we validated the perform-
ance of the pre-ECMO SAPS II for predicting 28-day
and 60-month mortality, according to the indication,
and confirmed the 28-day and 60-month cumulative sur-
vival rates using Kaplan-Meier analysis.
Results
Baseline and clinical characteristics of the study patients
Among the 65 patients who were included in this pre-
sented study, 35 (53.8 %) patients underwent E-CPR, 20
(30.8 %) underwent VA or V-AV ECMO, and 10
(15.4 %) underwent VV ECMO. The 28-day survival
rates were 28.6 % in the E-CPR group, 60 % in the VA
or V-AV ECMO group, and 90 % in the VV ECMO
group (Fig. 1).
The patients’ pre- and during-ECMO characteristics
are listed in Tables 1 and 2. The median patient age was
56 years (52 men, 13 women). Regarding the indications
for ECMO, AMI (28 patients, 43.1 %) was the most
common cause, and was followed by refractory septic
shock and traumatic respiratory failure. Among the 51
patients with arrest, the median duration of CPR was
55 min and E-CPR was performed in 35 patients. The
overall survival rate in the VV mode was higher than




Age, years 56.0 (42.5, 71.5)




Coronary artery disease 4
Chronic kidney disease 3
Cerebral vascular accident 3
Pulmonary disease 1
Diagnosis, n (survivors)
Acute cardiac failure 42 (18)
Acute myocardial infarction 28 (10)
Pulmonary thromboembolism 4 (3)
Unknown cardiac arrest 3 (0)
Other* 7 (5)
Refractory septic shock 9 (3)
Neurogenic circulatory failure 1 (0)
Acute respiratory failure 13 (10)
Traumatic respiratory failure 8 (8)
Sepsis related respiratory failure 3 (1)
Neurogenic pulmonary edema 1 (1)
Status asthmaticus 1 (0)
Arrest, n (survivors) 51 (17)
Out of hospital, n (survivors) 35 (15)
ED, n (survivors) 16 (2)
CPR time, min 55 (20, 72)
CPR-related complications‡ 22 (34 %)
E-CPR, n (survivors) 35 (10)
Pre-ECMO laboratory findings
pH 7.09 (6.94, 7.23)
PaO2/FiO2 54.84 (28.9, 80.0)
CK-MB 4.04 (1.80, 12.25)
Troponin-I 0.1 (0.03, 0.86)
BUN 15.4 (11.85, 20.85)
Creatinine 1.20 (0.95, 1.40)
Total bilirubin 0.87 (0.60, 1.38)
AST 55.0 (32.5, 120.5)
ALT 40.0 (24.0, 106.5)
Lactate 8.75 (6.10, 12.73)
IABP 10
SOFA score 13 (11, 14)
Pre-ECMO SAPS II 88 (70, 97)
Table 1 The patient characteristics before extracorporeal
membrane oxygenation (Continued)
Door to ECMO time†, min 93.0 (56.5, 182.0)
E-CPR 62.0 (49.0, 95.0)
Veno-arterial 157.0 (84.0, 348.0)
Veno-venous 126.0 (102.0, 206.0)
Continuous variables are reported as median (interquartile range)
CPR cardiopulmonary resuscitation, ED emergency department, E-CPR
extracorporeal cardiopulmonary resuscitation, ECMO extracorporeal membrane
oxygenation, BUN blood urea nitrogen, AST aspartate transaminase, ALT
alanine transaminase, IABP intraaortic balloon pump, SOFA Sequential Organ
Failure Assessment, SAPS II Simplified Acute Physiology Score II
*Hypothermia, malignant arrhythmia, dilated cardiomyopathy, ischemic
cardiomyopathy, commotio cordis, abdominal aortic aneurysm rupture
†Door to ECMO time: the time from arrival at the ED to ECMO implantation
‡Hypoxic brain damage, hemothorax, pulmonary hemorrhage, chest wall
compartment syndrome, chylothorax
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that in the VA or V-AV mode (21/52, 40 % vs. 10/13,
77 %, p = 0.018). Compared to the non-survivor group,
the survivor group had a longer ECMO duration
(72.5 min vs. 143.0 min, p = 0.001) and fewer blood
transfusions (packed red blood cells: 1.9 units/day vs. 1.0
units/day, p = 0.002; fresh frozen plasma: 1.0 units/day
vs. 0.3 units/day, p = 0.001). However, there were no dif-
ferences in the use of CCRT, type of anticoagulation
treatment, and complications between the survivor and
non-survivor groups (Table 3).
Predictors for mortality in patients with ECMO support at
the ED
In the logistic regression analyses, all 28-day variables
that were under consideration (hypertension, cardiac ar-
rest on arrival, E-CPR, CPR time, ECMO VA mode, lac-
tate, SOFA score, pre-ECMO SAPS II, and CPR-related
complications) were significantly higher in the non-
survivors, compared to the values in the survivors. How-
ever, in the multivariate analysis, only pre-ECMO
SAPS II was a statistically significant predictor (odds
ratio [OR]: 1.189; 95 % confidence interval [CI]:
1.032–1.370; p = 0.016) (Table 4).
The clinical relevance of pre-ECMO SAPS II as a pre-
dictor for 28-day mortality was further confirmed by the
subsequent ROC analyses. The area under the ROC
curve for pre-ECMO SAPS II was 0.852 (95 % CI:
0.753–0.951, p < 0.001), and the optimal cutoff value for
pre-ECMO SAPS II was 80 (sensitivity of 97.1 % and
specificity of 71.0 %), respectively (Fig. 2).
Validating the performance of pre-ECMO SAPS II for 28-day
and 60-month mortality
The cutoff value of 80 exhibited a statistically significant
difference for the 28-day and 60-month mortality rates in
the overall, E-CPR, and VA groups (28-day: p < 0.001, p =
0.004, p = 0.005; 60-month: p < 0.001, p = 0.004, p =
0.020) (Table 5). In the Kaplan-Meier analysis, the 28-
day and 60-month cumulative survival rates were lower
among the patients with a pre-ECMO SAPS II of ≤80,
compared to those with a pre-ECMO SAPS II of >80
(both, p < 0.001) (Fig. 3).
Discussion
The present study’s results demonstrated that pre-
ECMO SAPS II is an independent predictor for 28-day
mortality among patients with ECMO support at the
ED. In the validation of its performance, the cutoff value
of 80 exhibited statistically significant differences for the
28-day and 60-month mortality rates, especially in the
E-CPR and VA ECMO groups. Therefore, the pre-
ECMO SAPS II could be helpful for selecting patients
with refractory acute circulatory and/or respiratory fail-
ure who will respond to ECMO support at the ED.
Table 2 The characteristics of survivors and non-survivors during
extracorporeal membrane oxygenation support
Non-survivors Survivors p-value
n = 34 n = 31
ECMO modes 0.018
VA mode 31 21
Change from VA to VV - 1
Change from VA to V-AV 1 -
Change from VA to V-AV, and
then to VV
- 1
V-AV mode 2 1
Change from V-AV to VV 1 -
VV mode 1 9
Anticoagulants 0.179
Nafamostat mesilate 30 26
Heparin 2 5
ECMO run of ≤24 h 9 1 0.014a
Surgery after ECMO - 4 0.046a
ECMO duration, h 72.5 (23.8, 118) 143.0 (93, 212) 0.001
CRRT 18 (60 %) 5 (71 %) 0.687a
Daily blood transfusion, unit/d - -
Packed red blood cells 1.9 (0.9, 3.0) 1.0 (0.7, 1.3) 0.002
Fresh frozen plasma 1.0 (0.5, 2.4) 0.3 (0.0, 0.7) 0.001
Platelet concentrate 1.7 (0.0, 5.0) 1.3 (0.0, 3.3) 0.823
Length of stay
ICU 4 (2, 7) 18 (11, 30) <0.001
Hospital 4 (2, 7) 28 (20, 51) <0.001
aFisher’s exact test. Continuous variables are reported as median
(interquartile range)
ECMO extracorporeal membrane oxygenation, VA veno-arterial, VV veno-venous,
V-AV veno-arteriovenous, CRRT continuous renal replacement therapy, ICU
intensive care unit
Surgeries included two pulmonary artery thromboembolectomies, a left upper
lobectomy, and an aneurysm clipping via a left frontotemporal craniectomy
Table 3 A comparison of complications among survivors and
non-survivors
Non-survivors Survivors p-value
n = 34 n = 31
Cannula-related complications 2 2 1.000a
Cannula site bleeding 1 -
Leg ischemia 1 1
Thrombosis - 1
Acute renal failure 12 9 0.590
SIRS 1 - 1.000a
Gastrointestinal bleeding 3 2 1.000a
Cholecystitis - 1 0.477a
Intracranial hemorrhage 2 - 1.000a
aFisher’s exact test. SIRS, systemic inflammatory response syndrome
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The selection of appropriate candidates for ECMO
support requires serious consideration, due to the high
economic cost and labor intensive nature. A small num-
ber of recent studies have attempted to develop a scor-
ing system for identifying these patients. Schmidt et al.
evaluated the PRESERVE and RESP scores in their sur-
vival prediction model for patients who received ECMO
support in the ICU [10, 11]. However, there are several
limitations to applying these systems for patients in the
ED. First, those studies only enrolled patients with re-
spiratory failure, which inevitably led to most of the
ECMO being VV mode (PRESERVE VA mode: 133/
140 [95 %] and RESP VA mode: 1,928/2,355 [82 %]).
However, similar to our results, VA modes were ap-
plied more than VV modes for patients who received
ECMO support in the ED. Second, during E-CPR and
VA ECMO, it is difficult to assess mechanical ventila-
tion duration and settings. Third, Klinzing et al. dem-
onstrated that the RESERVE and RESP scoring
systems failed to predict mortality for patients who
were receiving VA ECMO [16]. In the present study, pre-
ECMO SAPS II significantly predicted the survival of pa-
tients who received VA ECMO and E-CPR. The VV
ECMO group exhibited a similar tendency, although the
result was not statistically significant.
Our survival rate results demonstrated better out-
comes, compared to those of previous studies. We sug-
gest that the discrepancies between these findings may
be related to patient enrollment. The majority of indica-
tions for VA or V-AV ECMO were for acute cardiac fail-
ure, especially AMI, and only a relatively small number
of patients with septic shock (which has a poor progno-
sis) were included. In contrast, the major indication for
VV ECMO was traumatic acute respiratory distress syn-
drome, which has a favorable prognosis.
Given the ongoing progress in the development of
ECMO equipment, cannula can easily and safely be im-
planted into patients’ peripheral vessels, which facilitates
the rapid application of ECMO. This rapid emergent
cardiopulmonary assistance technique can also facilitate
the appropriate testing and diagnosis, and thereby allow
for appropriate treatment [17–20]. In the present study,
43 % of the patients who received ECMO support at the
ED had presented with complications of refractory car-
diogenic shock or cardiac arrest due to AMI. These
Table 4 Univariate and multiple logistic regression analysis of pre-extracorporeal membrane oxygenation predictors of 28-day
mortality
Variable Univariate analysis Multivariate analysis
OR 95 % CI p-value OR 95 % CI p-value
Hypertension 3.857 1.312-11.337 0.014 1.921 0.123-29.942 0.641
Cardiac arrest on arrival 3.392 1.220-9.431 0.019 0.012 0.000-1.896 0.087
E-CPR 5.833 1.998-17.028 0.001 1.078 0.055-21.099 0.960
CPR time 1.021 1.000-1.041 0.047 1.002 0.955-1.051 0.941
VA/VV ECMO 14.211 1.665-121.316 0.015 4.626 0.023-925.946 0.571
Lactate 1.334 1.109-1.605 0.002 1.345 0.885-2.045 0.165
SOFA score 1.430 1.146-1.785 0.002 1.191 0.539-2.633 0.665
CPR related Cx 7.594 2.181-26.437 0.001 1.138 0.082-15.840 0.923
Pre-ECMO SAPS II 1.131 1.059-1.207 <0.001 1.189 1.032-1.370 0.016
In order to solve the multicollinearity problem, we excluded the variables that are included in SAPS II from the logistic regression analysi
E-CPR extracorporeal cardiopulmonary resuscitation, CPR cardiopulmonary resuscitation, VA veno-arterial, VV veno-venous, ECMO extracorporeal membrane
oxygenation, SOFA Sequential Organ Failure Assessment, SAPS II Simplified Acute Physiology Score II, Cx complications
Fig. 2 Receiver operating characteristics curves for pre-ECMO SAPS II
in predicting 28-day mortality. The figure shows the receiver operating
characteristics curve for pre-extracorporeal membrane oxygenation
(ECMO) Simplified Acute Physiology Score (SAPS) II scoring, with an
area under the curve of 0.852 (p < 0.001; 95 % CI: 0.753–0.951). At a
SAPS II cutoff value of 80, the sensitivity and 1-specificity were 0.971
and 0.290, respectively
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patients underwent PCI with ECMO, which provided a
35.7 % patient survival rate. Therefore, AMI that is ac-
companied by cardiogenic shock, or cases of cardiac ar-
rest that present with a high risk of mortality when
using conventional treatment methods, may be suit-
able for ECMO, which can facilitate appropriate diag-
nosis and treatment, and improve patient survival
rates [6, 21–25]. Furthermore, other studies have re-
ported that, in cases of in- and out-of-hospital cardiac
arrest with cardiac origin, E-CPR provided a survival
rate of 32.1–34.1 %, which is higher than that ob-
tained using conventional CPR [5, 7, 26].
Among the four patients with acute massive pulmon-
ary embolism who received ECMO in our study, one pa-
tient presented with out-of-hospital cardiac arrest and
was diagnosed with a massive pulmonary embolism after
the E-CPR. Unfortunately, this patient subsequently died
of hypoxic brain damage. Two of the three survivors
underwent pulmonary embolectomy after the ECMO,
while the other surviving patient underwent successful
medical treatment. For patients in near-fatal condition
(due to massive pulmonary embolisms), the survival rate
of medical or surgical treatment after ECMO is 62–70 %
[27, 28]. In these cases, the clinical decision to adminis-
ter ECMO, the reversibility of the underlying disease,
and the patient’s condition after ECMO all affect the
prognosis, and an aggressive diagnosis and treatment of
the underlying disease are critical to patient survival [22].
In this present study, 33 % of the patients with acute
sepsis-related circulatory and/or respiratory failure
Table 5 Validation of SAPS II for 28-day and 60-month mortality according to the indication



























SAPS II ≤80 22 (71.0) 1 (2.9) 5 (50.0) 1 (4.0) 8 (66.7) 0 (0.0) 9 (100.0) 0 (0.0)
SAPS II >80 9 (29.0) 33 (97.1) 5 (50.0) 24 (96.0) 4 (33.3) 8 (100.0) 0 (0.0) 1 (100.0)
60-month
mortality
SAPS II ≤80 19 (79.2) 4 (9.8) 4 (66.7) 2 (6.9) 7 (70.0) 1 (10.0) 8 (100.0) 1 (50.0)
SAPS II >80 5 (20.8) 37 (90.2) 2 (33.3) 27 (93.1) 3 (30.0) 9 (90.0) 0 (0.0) 1 (50.0)
Fig. 3 Kaplan-Meier analysis for a pre-ECMO SAPS II score of 80 in predicting 28-day and 60-month mortality. The risk of 28-day and 60-month
mortality among patients with SAPS II of ≤80 was lower than that of patients with SAPS II of >80 (both, p < 0.001)
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ultimately survived. Although the use of ECMO in pa-
tients with sepsis remains controversial, it may be effect-
ive for use in a select group of patients [8, 29]. In
addition, the survival rate for patients with acute respira-
tory failure was 77 % (10/13), compared to 40 % (21/52)
for patients with acute circulatory failure, which is due
to the fact that all 8 patients with traumatic respiratory
failure who received ECMO ultimately survived. There-
fore, VV ECMO is very effective in treating patients with
severe thoracic trauma and acute lung failure from vari-
ous causes [3, 9].
As patients in the ED require rapid diagnosis and
treatment, it is difficult to determine appropriate ECMO
implantation standards and identify patients with acute
cardiopulmonary failure who will not respond to con-
ventional treatment. Although pre-ECMO SAPS II is
widely used to predict mortality among ICU patients,
this can be also useful for predicting ED patient mortal-
ity in cases of cardiovascular and respiratory illnesses
[30]. Although the median pre-ECMO SAPS II in our
study was 88, which predicted an extremely high mortal-
ity rate (96.1 %), the 28-day and 60-month overall mor-
tality rates for our patients were 52.3 % and 63.1 %.
Furthermore, these mortality rates for patients with a
pre-ECMO SAPS II of ≤80 were 2.9 % and 20.8 %, re-
spectively. Therefore, we believe that the pre-ECMO
SAPS II score can lead to the appropriate selection of pa-
tients for ECMO support, and improve patient outcomes.
This study had several limitations. First, it was based at
a single center, which limits the generalizability of the
findings. Second, the study population was small, and the
underlying diseases were diverse. Third, in VA ECMO, a
relatively small number of patients with refractory septic
shock were enrolled in this study. Thus, further studies
are needed to determine whether our findings can be ac-
curately applied to these patients. Finally, we performed a
retrospective analysis, and additional prospective multi-
center studies are needed to validate our findings.
Conclusions
Pre-ECMO SAPS II could be helpful for selecting patients
with refractory acute circulatory and/or respiratory failure
who will respond to ECMO support at the ED.
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